Drug Information

Drug (ID: DG01731) and It's Reported Resistant Information

Name	Bevacizumab/Gefitinib
Synonyms	Bevacizumab/Gefitinib Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Lung cancer [ICD-11: 2C25]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Key Molecule: Epidermal growth factor receptor (EGFR)			[1]
Molecule Alteration	Complex-indel	p.H773_V774delinsLM (c.2317_2322delinsCTTATG)	Molecule Info
Sensitive Disease	Lung adenocarcinoma [ICD-11: 2C25.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data

References

Ref 1	Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complexLung Cancer. 2018 Jul;121:1-4. doi: 10.1016/j.lungcan.2018.04.006. Epub 2018 Apr 5.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.